News

2017.08.03 Press Release

Development of a novel catheter ablation system

A research group led by Professor Hiroaki Shimokawa of the Department of Cardiovascular Medicine in Tohoku University Graduate School of Medicine have reported the effeciency and safety of shock-wave (SW) catheter ablation (SWCA) system as a novel non-thermal therapy in pigs in vivo.
Although the radiofrequency catheter ablation (RFCA) is widely used for the treatment of tachyarrhythmias, it has three fundamental weaknesses as a thermal ablation system, including a limited lesion depth, myoendocardial injury linking to thromboembolism, and prolonged inflammation followed by subsequent recurrences. In order to overcome these limitations, they have been developing a SWCA system as a novel non-thermal therapy. In the present study, they validated new SWCA system with increased SW intensity. They demonstrated that SWCA system is superior to the RFCA in terms of lesion depth, myoendocardial injury and tissue repair process. The SWCA system may be a promising option to compensate for the weaknesses of the current RFCA therapy.
The research results have been published online in EP Europace on Aug.2, 2017 (GTM). The paper’s title is “Development of a novel shock wave catheter ablation system-A validation study in pigs in vivo-”

Publication Details:
Authors:Michinori Hirano, Hiroaki Yamamoto, Yuhi Hasebe, Koji Fukuda,
Susumu Morosawa, Hirokazu Amamizu, Kazuma Ohyama, Hironori Uzuka,
Kazuyoshi Takayama, Hiroaki Shimokawa
Title: Development of a novel shock wave catheter ablation system-A validation study in pigs in vivo-
Journal: EP Europace

For enquiries about this research:
Hiroaki Shimokawa
Professor,
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
Email: shimo@cardio.med.tohoku.ac.jp

For media enquiries:
Hitoshi Inada
Public Relations Office
Tohoku University Graduate School of Medicine
Tel: +81-22-717-7891
E-mail: hinada@med.tohoku.ac.jp